Patient: Page 2
-
iStock via Getty Images
These 4 drugs had tons of promise — and they flopped. What happened?
No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.
By Alexandra Pecci • Feb. 13, 2024 -
Stock via Getty Images
Tonix closes in on the first new fibromyalgia drug in more than a decade
In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.
By Kelly Bilodeau • Jan. 29, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024 -
Stock via Getty Images
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Dan Kitwood/Getty Images via Getty Images
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.
By Michael Gibney • Jan. 25, 2024 -
Stock via Getty Images
Breast cancer tops list of most studied diseases
The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.
By Kelly Bilodeau • Jan. 24, 2024 -
Stock via Getty Images
Controversial challenge trials offer unparalleled innovation — with ethical bumps
Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.
By Kelly Bilodeau • Jan. 22, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Getty Images via Getty Images
An enduring COVID mystery: Why some do fine and others die
The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.
By Alexandra Pecci • Jan. 17, 2024 -
Stock via Getty Images
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Stock via Getty Images
OpinionPharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
E+ via Getty Images
How J&J is tackling a ‘secondary pandemic’ in the Black community
J&J is leading a grassroots effort to improve mental health access and care.
By Alexandra Pecci • Jan. 8, 2024 -
Stock via Getty Images
Regulatory twists and turns are coming for biopharma in 2024
New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.
By Kelly Bilodeau • Jan. 8, 2024 -
iStock via Getty Images
Alzheimer’s research is hot, but successful patient recruitment will determine its future
Key strategies for bringing more patients into the clinical trial fold.
By Kelly Bilodeau • Jan. 4, 2024 -
Stock via Getty Images
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Massachusetts General Hospital
Deep DiveAs ALS research booms, one treatment center finds itself in the spotlight
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
By Jacob Bell • Dec. 22, 2023 -
Stock via Getty Images
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023 -
Stock via Getty Images
5 noteworthy pharma AI investments in 2023
The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.
By Alexandra Pecci • Dec. 19, 2023 -
Permission granted by Babson Diagnostics
Babson gets one step closer to delivering on Theranos-like blood testing
A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.
By Kelly Bilodeau • Dec. 18, 2023 -
Stock via Getty Images
Study suggests PBMs are gaming pharmacy system to overcharge for drugs
Markups for generics can be as high as 7,000%, the researchers said.
By Alexandra Pecci • Dec. 15, 2023 -
Permission granted by Quita Highsmith
Q&AThe many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
By Michael Gibney • Dec. 14, 2023 -
iStock via Getty Images
What’s being done to prepare for the next pandemic?
Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.
By Kelly Bilodeau • Dec. 13, 2023 -
Permission granted by FNIH
Q&AA former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
By Meagan Parrish • Dec. 13, 2023 -
Permission granted by Adam Lenkowsky
Q&ABristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023
Previous
